Spero Therapeutics, Inc.
SPRO
$2.33
$0.010.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -61.91% | -58.99% | -59.83% | -53.77% | 37.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -61.91% | -58.99% | -59.83% | -53.77% | 37.01% |
| Cost of Revenue | 6.84% | 57.67% | 103.79% | 134.06% | 243.17% |
| Gross Profit | -540.30% | -392.64% | -384.83% | -376.44% | -125.06% |
| SG&A Expenses | 3.69% | 5.79% | 1.89% | -7.24% | -9.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.38% | 7.52% | 40.14% | 56.46% | 42.30% |
| Operating Income | -3,984.60% | -370.16% | -370.26% | -370.59% | -152.27% |
| Income Before Tax | -1,306.26% | -367.30% | -368.31% | -369.90% | 504.69% |
| Income Tax Expenses | 198.97% | -100.00% | -100.00% | -100.00% | -95.61% |
| Earnings from Continuing Operations | -1,347.82% | -407.08% | -398.09% | -400.65% | 317.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,347.82% | -407.08% | -398.09% | -400.65% | 317.66% |
| EBIT | -3,984.60% | -370.16% | -370.26% | -370.59% | -152.27% |
| EBITDA | -4,532.95% | -367.10% | -366.85% | -366.60% | -137.87% |
| EPS Basic | -1,076.54% | -390.60% | -390.00% | -397.61% | 756.84% |
| Normalized Basic EPS | -1,011.54% | -297.01% | -313.30% | -317.34% | -44.86% |
| EPS Diluted | -1,107.59% | -393.01% | -391.83% | -399.55% | 731.58% |
| Normalized Diluted EPS | -1,033.07% | -297.79% | -314.00% | -318.07% | -46.13% |
| Average Basic Shares Outstanding | 3.55% | 3.22% | 2.92% | 2.53% | 3.91% |
| Average Diluted Shares Outstanding | 3.50% | 3.17% | 2.87% | 2.48% | 3.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |